Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma
T Look, E Puca, M Bühler, D Kirschenbaum… - Science Translational …, 2023 - science.org
Glioblastoma is the most aggressive primary brain tumor with an unmet need for more
effective therapies. Here, we investigated combination therapies based on L19TNF, an …
effective therapies. Here, we investigated combination therapies based on L19TNF, an …
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
T Weiss, E Puca, M Silginer, T Hemmerle… - Science translational …, 2020 - science.org
Glioblastoma is a poorly immunogenic cancer, and the successes with recent
immunotherapies in extracranial malignancies have, so far, not been translated to this …
immunotherapies in extracranial malignancies have, so far, not been translated to this …
[HTML][HTML] T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
V Turco, K Pfleiderer, J Hunger, NK Horvat… - Nature …, 2023 - nature.com
Glioblastoma, the most common and aggressive primary brain tumor type, is considered an
immunologically “cold” tumor with sparse infiltration by adaptive immune cells …
immunologically “cold” tumor with sparse infiltration by adaptive immune cells …
[HTML][HTML] Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
A Poli, J Wang, O Domingues, J Planagumà, T Yan… - Oncotarget, 2013 - ncbi.nlm.nih.gov
Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6
months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and …
months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and …
The impact of macrophage-and microglia-secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment
WH Meisen, ES Wohleb, AC Jaime-Ramirez… - Clinical Cancer …, 2015 - AACR
Purpose: Oncolytic herpes simplex viruses (oHSV) represent a promising therapy for
glioblastoma (GBM), but their clinical success has been limited. Early innate immune …
glioblastoma (GBM), but their clinical success has been limited. Early innate immune …
[HTML][HTML] Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain …
Y Mineharu, AKMG Muhammad, K Yagiz, M Candolfi… - …, 2012 - Elsevier
Immune-mediated gene therapy using adenovirus expressing Flt3 ligand and thymidine
kinase followed by ganciclovir administration (Flt3/TK) effectively elicits tumor regression in …
kinase followed by ganciclovir administration (Flt3/TK) effectively elicits tumor regression in …
Immunotherapy of malignant glioma by noninvasive administration of TLR9 agonist CpG nano‐immunoadjuvant
J Wei, D Wu, S Zhao, Y Shao, Y Xia, D Ni… - Advanced …, 2022 - Wiley Online Library
Immunotherapy with toll like receptor 9 (TLR9) agonist CpG ODN offers an emergent
strategy to treat life‐threatening malignant glioma. CpG is typically applied invasively by …
strategy to treat life‐threatening malignant glioma. CpG is typically applied invasively by …
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models
Glioblastoma multiforme (GBM) is the most common and lethal brain tumor characterized by
a strongly immunosuppressive tumor microenvironment (TME) that represents a barrier also …
a strongly immunosuppressive tumor microenvironment (TME) that represents a barrier also …
TGFβ treatment enhances glioblastoma virotherapy by inhibiting the innate immune response
J Han, X Chen, J Chu, B Xu, WH Meisen, L Chen… - Cancer research, 2015 - AACR
Oncolytic viruses, including oncolytic herpes simplex virus (oHSV), have produced
provocative therapeutic responses in patients with glioblastoma, the most aggressive brain …
provocative therapeutic responses in patients with glioblastoma, the most aggressive brain …
Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand
M Ehtesham, P Kabos, MAR Gutierrez, NHC Chung… - Cancer research, 2002 - AACR
Current therapies for gliomas fail to address their highly infiltrative nature. Standard
treatments oftenleave behind microscopic neoplastic reservoirs, resulting in eventual tumor …
treatments oftenleave behind microscopic neoplastic reservoirs, resulting in eventual tumor …